Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Herein we show that phosphorus repletion in patients with hypophosphatemia receiving anti-CD19 chimeric antigen receptor T-cell therapeutics was associated with significantly decreased immune effector cell-associated neurotoxicity syndrome (ICANS) incidence and symptom duration. Given the significant morbidity associated with ICANS and lack of targeted interventions, hypophosphatemia may serve as both a useful biomarker and an inexpensive intervention for ICANS.
Authors
- Esther H. Nie (ORCID: https://orcid.org/0000-0002-2280-5905)
- Alexandru Socolov
- Mark R. Hanudel (ORCID: https://orcid.org/0000-0002-5886-8078)
- Theodore B. Moore (ORCID: https://orcid.org/0000-0002-7909-610X)
- Pénélope Lafeuille (ORCID: https://orcid.org/0009-0008-7036-2257)
- Jacob Aptekar (ORCID: https://orcid.org/0000-0003-0525-9014)
- Jack Pengfei Tang (ORCID: https://orcid.org/0000-0003-4479-9638)
- Theodore S. Nowicki (ORCID: https://orcid.org/0000-0002-3815-6137)
- Sheila S. Diamond (ORCID: https://orcid.org/0009-0003-1917-449X)
Institutions
- University of California, Los Angeles (US)
- Los Angeles Medical Center (US)
- Institute of Neuroimmunology of the Slovak Academy of Sciences (SK)
- Broad Center (US)
- Medidata (United States) (US)
- Dassault Systèmes (France) (FR)
- Stanford University (US)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2024-09-13
- DOI
- https://doi.org/10.1158/2767-9764.crc-24-0250
- Citations
- 3
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.85
Funders
- National Institutes of Health
- Hyundai Hope On Wheels